Bristol Myers Squibb Partners With Anthropic to Deploy Claude Across Global Operations
Advertisement
Under the agreement, Claude will be rolled out to more than 30,000 Bristol Myers Squibb employees and positioned as a shared intelligence layer across research, manufacturing, and commercial functions.
Bristol Myers Squibb has entered into a broad enterprise agreement with AI company Anthropic to deploy its Claude platform across global operations, marking a major expansion of artificial intelligence into pharmaceutical R&D and business workflows.
Under the agreement, Claude will be rolled out to more than 30,000 Bristol Myers Squibb employees and positioned as a shared intelligence layer across research, manufacturing, and commercial functions.
The company said the initiative represents a shift from traditional chatbot-based AI tools toward agentic AI systems capable of reasoning and supporting complex enterprise workflows. The deployment will also include Anthropic’s developer tool, Claude Code, to accelerate internal software development and data integration.
Bristol Myers Squibb said it plans to apply Claude’s AI capabilities to drug discovery processes, including target identification and lead molecule optimization across its core therapeutic areas such as oncology, hematology, neuroscience, and immunology.
The company has set an internal goal of reducing the time required from target selection to lead molecule identification by half, according to its leadership.
In clinical development, the AI system is expected to support automation in trial documentation and potentially reduce the time between data lock and regulatory submission. Industry estimates have suggested that agentic AI could improve clinical development productivity by 35% to 45% over the next five years.
In manufacturing operations, the company is evaluating AI use cases for quality control, root-cause analysis, compliance documentation, and batch release processes. On the commercial side, BMS plans to use AI to convert field insights into structured data to support healthcare provider engagement.
Greg Myers, chief digital and technology officer at Bristol Myers Squibb, said the collaboration aims to connect fragmented data systems across the organization and unlock embedded knowledge across decades of research and operations.
The rollout comes amid a broader wave of AI adoption across the pharmaceutical industry, with companies including Merck & Co., Novo Nordisk, and others entering large-scale partnerships with major AI firms to strengthen drug development and operational efficiency.
Industry analysts note that pharmaceutical companies are increasingly competing to build integrated AI ecosystems spanning discovery, clinical trials, and manufacturing as part of long-term digital transformation strategies.
Stay tuned for more such updates on Digital Health News
